<unk> , sold under the brand name Exjade & Asunra (in injectable form) & Oleptiss (Tablet formulation) both by Novartis among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the United States for this purpose. It was approved by the U.S. Food and Drug Administration (FDA) in November 2005. According to the FDA (May 2007), kidney failure and cytopenias have been reported in patients receiving<unk>  tablets for oral suspension. It is approved in the European Union by the European Medicines Agency (EMA) for children six years and older for chronic iron overload from repeated blood transfusions. It is on the World Health Organization's List of Essential Medicines. In July 2020, Teva decided to discontinue<unk> . It is available as a generic medication.
Deferasirox
Brodifacoum
Deferiprone
Fermagate
Dotinurad
Co-codaprin
Disufenton sodium
Gadobenic acid